Related Experiment Video
Updated: Jan 15, 2026
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Risks and Implications of Multiple Actionable Pathogenic Germline Variants Discovered by Panel-Based Cancer
Catherine Neumann1, Demitrios Dedousis1,2, Michael J Hall1
1Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA.
Purpose:
Growing use of multigene panels (MGPs) is increasing the number of patients identified with multiple pathogenic germline variants (PGVs) in cancer predisposition genes. This study characterizes the landscape of patients with multiple PGVs and identifies clinical settings where multiple PGVs affect management.
Materials And Methods:
This is a single-institution retrospective cohort analysis comprising patients seen in the Department of Clinical Genetics and consented to the Risk Assessment Program (RAP) Registry who were evaluated with a MGP and found to have multiple PGVs.
Results:
All patients tested between January 1, 2014, and January 1, 2024, and found to have multiple PGV are included. Sixty-four patients (64/7,961, 0.8%) from 58 families carried multiple PGVs, 22/64 (34%) patients carried at least two PGVs in high- or moderate-risk genes, and 33/64 (52%) carried at least two PGVs that result in potential management changes. Five percent (30/557) of all patients with a PGV in BRCA1 or BRCA2 also carried an additional PGV, while 7% (19/284) of patients with a PGV in a mismatch repair (MMR) gene also carried an additional PGV. Ten patients from nine unrelated families had both a PGV in BRCA1 or BRCA2 as well as a PGV in an MMR gene.
Conclusion:
Although the overall percentage of patients undergoing clinical genetic testing with multiple PGVs is small, a significant fraction of these patients could benefit from medical management changes because of the identification of multiple PGVs.
More Related Videos
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
Related Concept Videos
02:59Cancer Prevention
Some...
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...